Search the Newsreel

Akebia Therapeutics (AKBA) AGM 2026 Summary

This article summarizes Akebia Therapeutics' (AKBA) 2026 Annual General Meeting (AGM), detailing the agenda, including the election of Class III directors, approval of an increase in authorized capital, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the …

Akebia Therapeutics (AKBA) Stock Price Sinks As Losses Deepen Value Doubts

Akebia Therapeutics (AKBA) stock fell 26% to US$0.95 following a Q2 2026 earnings report showing revenue decline and a net loss, raising concerns about its valuation. While the company's Vafseo product is showing strong growth, the overall revenue fall and decline in Auryxia sales, …

H.C. Wainwright reiterates Buy on Akebia stock, $6 target

H.C. Wainwright reiterates Buy on Akebia stock, $6 target By Investing.com

Earnings call transcript: Akebia Therapeutics posts mixed Q2 2026 results as stock falls

Akebia Therapeutics reported its second-quarter earnings, highlighting significant revenue growth for its Vafseo anemia treatment and positive interim results from the VOICE study, which met its stopping criteria for non-inferiority and superiority. The company also detailed advancements in its rare kidney disease pipeline with …

Akebia Ther earnings beat by $0.01, revenue fell short of estimates

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Akebia Therapeutics announced strong second-quarter 2026 financial results, with Vafseo net product revenues growing to $21.3 million and over 10,500 patients on therapy. The company also highlighted significant advancements in its rare kidney disease pipeline, including the initiation of a Phase 2 trial for …

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA) reported granting options to purchase 61,000 shares of common stock to two new employees on July 31, 2026. These grants, made as an inducement for employment, comply with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $1.32 …

Akebia Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview

Akebia Therapeutics Inc is anticipated to report a loss of 4 cents per share. This information comes from a Refinitiv earnings preview. The full article is available through a TradingView subscription.

Two New Akebia Hires Get Stock Options With 4-Year Vesting

Akebia Therapeutics (Nasdaq: AKBA) granted stock options for an aggregate of 61,000 shares to two new employees on July 31, 2026. These inducement awards, granted under Nasdaq Listing Rule 5635(c)(4), have an exercise price of $1.32 per share and will vest over four years, …

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

Akebia Therapeutics has initiated a Phase 2 basket trial to evaluate ebribafusp, a next-generation complement inhibitor, for rare kidney diseases such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial aims to assess the safety, efficacy, and pharmacokinetics of weekly subcutaneous dosing, focusing …

Akebia Therapeutics And 2 Promising Penny Stocks To Watch

This article identifies Akebia Therapeutics (AKBA), GoodRx Holdings (GDRX), and Snap (SNAP) as promising penny stocks to watch, despite their current unprofitability and financial challenges. It highlights their market caps, revenues, recent developments, and financial health, noting their potential for growth alongside inherent risks. …

Akebia Therapeutics (AKBA) to Announce Earnings on Thursday

Akebia Therapeutics (AKBA) is scheduled to announce its Q2 2026 earnings before market open on Thursday, August 6th, with analysts expecting a loss of ($0.03) per share and revenue of $48.8520 million. The bi

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics will announce its second quarter 2026 financial results. The company will also hold a conference call and webcast to discuss these results and provide an update on recent business developments.

Akebia Therapeutics, Inc. Revenue Breakdown – BX:AX9

Akebia Therapeutics, Inc. (BX:AX9) generated 187.25 million CHF last year, with its Innovative Therapeutics segment being the top performer. All of this revenue came from the United States market, indicating a focused geographic revenue stream. This represents an increase from 145.48 million CHF the …

Akebia plans Aug. 5 webcast after markets close to discuss results

Akebia Therapeutics (Nasdaq: AKBA) will release its second-quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. The company will host a conference call at 4:30 p.m. EDT on the same day to discuss the results and recent business highlights, accessible …

AKBA|Akebia Therapeutics Inc|Price:1.275|Chg%:-0.005

Akebia Therapeutics Inc (AKBA) has a healthy fundamental outlook and high growth potential, with its valuation considered fairly valued. Despite strong analyst ratings with a "Strong Buy" consensus and a high institutional ownership, the stock is currently trading sideways. The company is a biopharmaceutical …

Akebia Therapeutics Inc (AKBA) Income Statement

This article provides the quarterly and annual income statement for Akebia Therapeutics Inc (AKBA), offering detailed financial data such as total revenue, operating expenses, special income, and net income stretching back to FY2012Q4. It highlights the company's financial performance, including a fiscal year 2025 …

Akebia Therapeutics Inc (AKBA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Akebia Therapeutics Inc's (AKBA) stock performance, market capitalization, and dividend history. It highlights that the company has not distributed any dividends over the past five years. The page also offers general financial data and company information for AKBA.

Akebia Therapeutics Inc (AKBA) Institutional Confidence

Akebia Therapeutics Inc (AKBA) has an institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion increased by 1.21% quarter-over-quarter to 46.96%. James Simons is the largest institutional shareholder, holding 0.68% of outstanding shares, while …

Akebia Therapeutics, Inc. Revenue Breakdown – SWB:AX9

Akebia Therapeutics, Inc. (SWB:AX9) generated 201.10 million EUR in revenue last year, primarily from its Innovative Therapeutics segment. The United States was the largest contributor to this revenue, accounting for 201.10 million EUR. This represents an increase from the previous year's revenue of 154.73 …

Akebia Therapeutics (AKBA) Q2 2024 earnings summary

Akebia Therapeutics (AKBA) reported a narrowed net loss in Q2 2024, driven by lower R&D and cost of goods sold, with total revenue at $43.6M. The company’s new drug, Vafseo, received FDA approval and is set for a U.S. launch in January 2025, while …

Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Declines By 34.3%

Short interest in Akebia Therapeutics (NASDAQ:AKBA) significantly decreased by 34.3% in June, totaling 19.2 million shares. This represents about 7.5% of the company's shares sold short, with a days-to-cover ratio of 2.7. The article also notes an insider stock sale by CFO Erik Ostrowski …

Akebia Therapeutics (NASDAQ:AKBA) Shares Pass Above Fifty Day Moving Average - Here's What Happened

Akebia Therapeutics (NASDAQ:AKBA) shares have surpassed their 50-day moving average, trading as high as $1.41 after crossing the $1.11 mark with significant trading volume. Analyst sentiment is mixed, with some downgrades and reiterations of bullish views, leading to a consensus "Hold" rating and an …

H.C. Wainwright reiterates Akebia stock rating on trial results

Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch

Earnings call transcript: Akebia Therapeutics Q1 2026 reports EPS miss, stock falls

Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results

Akebia Therapeutics (AKBA) Is Down 14.5% After Swing To Q1 Loss And Share Increase Plan

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

H.C. Wainwright reiterates Akebia Therapeutics stock rating at buy

In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook